Proactive Investors - Run By Investors For Investors

OptiBiotix names food industry heavy hitter as its new chairman

Former Express Dairies and Arla Foods chief executive Neil Davidson will take over from Adam Reynolds next month
boardroom table
Davidson brings to the boardroom table significant FTSE 100 experience

Life sciences group OptiBiotix Health plc (LON:OPTI) is recruiting a food industry heavy hitter to the role of chairman.

Former Express Dairies and Arla Foods chief executive Neil Davidson will take over from Adam Reynolds next month.

Currently a non-executive with the supermarket giant Wm Morrison (LON:MRW), he has also been an independent director at the housebuilder Persimmon (LON:PSN).

It means the new boardroom hire brings with him significant FTSE 100 experience – although he also chaired AIM-quoted Produce Investments.

Personal interest in innovation 

OptiBiotix said Davidson “has a personal interest in the development and commercialisation of technology to improve health”. 

That would appear to make him the ideal fit with the Opti, a pioneer of the human microbiome found in the gut.

It is using its knowledge and discoveries to develop healthy sweeteners and natural alternatives to current drugs for cholesterol and diabetes.

Chief executive Stephen O’Hara said of the chairman-elect: “His network of contacts and wealth of experience on the board of some of the UK's largest public companies will help guide OptiBiotix as it builds a microbiome business in what is forecast to be one of the world's fastest growth areas.

“The board anticipates a future where microbiome products will be at the forefront of preventing, managing and treating many of today's chronic lifestyle disease and we hope under Neil's guidance OptiBiotix will continue to be one of the world's leaders in this exciting and emerging field.”

The shares rose 3% in morning trade to 69.37p, valuing the business at £52mln.

---adds share price---

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use